英国国家尿黑酸尿症中心数据分析:尿黑酸尿症中骨质疏松的频率、诊断、发病机制与管理
研究分析了英国国家尿黑酸尿症中心87例患者,基线时39例患者共48处骨折,骨质疏松患病率股骨颈3.1%、全髋10.8%、腰椎24.7%,脆性骨折患病率44.8%。尼替西农联合抗骨吸收治疗使CT骨密度显著升高,但骨折数反而多于单用尼替西农组和未治疗组;作者认为DXA不如腰椎定量CT可靠。
要点
- 尿黑酸尿症患者脆性骨折患病率44.8%,骨质疏松患病率股骨颈3.1%、全髋10.8%、腰椎24.7%。
- 骨折组褐黄病评分升高(p<0.05),腰椎CT骨密度与骨折呈负相关(R=-0.28;p<0.05)。
- 尼替西农联合抗骨吸收治疗使CT股骨颈、全髋和腰椎骨密度均显著升高,但骨折数多于单用尼替西农组和未治疗组(p<0.05)。
核心结论
- 骨量减少和脆性骨折在尿黑酸尿症中常见。
- 抗骨吸收治疗提高了尿黑酸尿症患者的骨密度,但未减少脆性骨折。
- 在尿黑酸尿症中,腰椎DXA骨密度测量不如定量CT可靠。
研究设计与样本
- 研究纳入2007年6月至2020年3月在英国国家尿黑酸尿症中心就诊的87例尿黑酸尿症患者。
- 基线(开始尼替西农2 mg时)及此后每年进行问卷分析、DXA以及股骨颈、全髋和腰椎的CT骨密度测定,并采集血、尿标本进行化学检测,生成CT骨密度Z评分。
主要发现
- 基线时39例患者共48处骨折。
- 骨质疏松患病率股骨颈3.1%、全髋10.8%、腰椎24.7%,脆性骨折患病率44.8%。
- 骨折组褐黄病评分升高(p<0.05);腰椎CT骨密度与骨折呈负相关(R=-0.28;p<0.05),骨折组腰椎CT骨密度显著更低(p<0.002)。
- 单用尼替西农后,CT股骨颈和CT全髋骨密度显著下降(分别为p<0.05和p<0.01)。
- 尼替西农联合抗骨吸收治疗后,CT股骨颈、CT全髋和CT腰椎骨密度均显著升高(分别为p<0.05、p<0.05和p<0.001);但尼替西农联合抗骨吸收治疗组骨折数多于尼替西农组和未治疗组(p<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Osteoporosis and fractures are common features of alkaptonuria. INTRODUCTION: A large cohort of alkaptonuria (AKU) patients was studied to better recognise and characterise osteoporosis and fractures in AKU. METHODS: Assessments including questionnaire analysis, DEXA and CT densitometry at the neck of femur (FN), total hip (TH) and lumbar spine (LS) were performed on patients at baseline when 2 mg nitisinone was commenced, and yearly thereafter. Blood and urine samples were collected for chemical measurement. CT BMD Z-scores were generated. RESULTS: Between June 2007 and March 2020, 87 AKU patients attended the NAC. At baseline, there were 48 fractures in 39 patients. Prevalence of osteoporosis was 3.1 at FN, 10.8 at TH and 24.7% at LS respectively. Prevalence of fragility fractures was greatly increased at 44.8%. The group with fractures showed increased ochronosis scores (p < 0.05). CT LS showed an inverse relationship with fractures (R = - 0.28; p < 0.05). CT LS was significantly lower in the fracture group (p < 0.002). Following nitisinone only, CT FN and CT TH decreased significantly (p < 0.05 and 0.01 respectively). Following nitisinone plus antiresorptive therapy, CT FN, CT TH and CT LS all increased significantly (p < 0.05, 0.05 and 0.001 respectively). However, patients on nitisinone plus antiresorptive had more fractures than nitisinone and no-treatment groups (p < 0.05). CONCLUSIONS: Osteopenia and fragility fractures are common in AKU.. Anti-resorptive therapy increased BMD in AKU without decreasing fragility fractures. Bone densitometry measurements by DXA are less reliable than quantitative CT at the LS in AKU.
引用
- Ranganath LR, Khedr M, Vinjamuri S, et al. Frequency, diagnosis, pathogenesis and management of osteoporosis in alkaptonuria: data analysis from the UK National Alkaptonuria Centre. Osteoporos Int. 2020. PMID: 33118050. doi:10.1007/s00198-020-05671-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。